Liminatus Pharma, Inc. filed an amendment to its Certificate of Incorporation to effect a 1-for-50 reverse stock split of its common stock, effective August 20, 2026. The action addresses Nasdaq delisting risks related to minimum bid price and market value requirements following the company's transfer from the Nasdaq Global Market to the Nasdaq Capital Market on August 4, 2026. Outstanding shares are expected to decrease from approximately 67.1 million to 1.3 million, with fractional shares rounded up to whole shares without cash payment. The company operates in the biotechnology industry, developing immune-modulating cancer therapies.

Liminatus Pharma, Inc. reports that following its merger with InnocsAI LLC, it believes its stockholders' equity exceeds $2.5 million, satisfying a key Nasdaq continued listing standard. The company is awaiting a formal compliance determination from the exchange but notes that even if compliant, Nasdaq will monitor ongoing adherence to equity requirements. Failure to demonstrate compliance at the next periodic report could result in future delisting proceedings. Liminatus Pharma operates in the biotechnology industry, focusing on drug discovery and development.

Liminatus Pharma, Inc. received notice from Nasdaq on July 20, 2026, that it failed to regain compliance with the $1 minimum bid price rule and is ineligible for a second 180-day extension. The company held a hearing on June 30, 2026, to request an extension, but the Nasdaq Hearings Panel has not yet issued a final decision regarding continued listing. The company must submit a written response to the Panel by July 27, 2026. Additionally, a proxy statement filed on July 13, 2026, seeks stockholder authorization for a reverse stock split at the August 3, 2026, annual meeting. Liminatus Pharma, Inc. is a pharmaceutical company.

Liminatus Pharma, Inc. entered into an Amended and Restated Merger Agreement with InnocsAI LLC and NamChul Jung to restructure a previously announced transaction. On July 2, 2026, the company consummated the merger, acquiring InnocsAI by issuing 11,188,729 shares of common stock and 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock. The Series A Preferred Stock is convertible into 10,000 shares of common stock per share and requires stockholder approval for conversion. Liminatus Pharma, Inc. is a pharmaceutical company focused on drug development and research.